Sign in to view content

Anti-VEGF treatment switch in DME and nAMD: a comparison of aflibercept versus ranibizumab after a single-dose switch

Estephania Feria, MD

Video
Published 2019

Related

Clinical Outcomes of Eyes with Diabetic Macular Edema Switched from Aflibercept to Ranibizumab Therapy
Michael A Klufas, MD
On Demand Cases, Courses, and Papers
2019
Switching to Combination OPT-302 With Aflibercept From Prior Anti-VEGF-A Monotherapy in Eyes With Persistent Diabetic Macula Edema (DME)
David S. Boyer, MD
Annual Meeting Talks
2020
Outcomes of Patients with DME and Baseline BCVA 20/50 or Worse or 20/40 or Better Treated with Aflibercept 8 mg and 2 mg in the Phase 2/3 PHOTON Trial
Diana V Do, MD, FASRS
Updates from the Field
2024

Category: AMD-Neovascular

See more